Donald L Durden

InstitutionLevine Cancer Institute
AddressCharlotte
North Carolina
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 1 Covid-19 publications, with a maximum of 1 publications in January 2021
    All Publications
    Bar chart showing 45 publications over 18 distinct years, with a maximum of 7 publications in 2014
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Pathania AS, Prathipati P, Abdul BA, Chava S, Katta SS, Gupta SC, Gangula PR, Pandey MK, Durden DL, Byrareddy SN, Challagundla KB. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. Theranostics. 2021; 11(2):731-753. PMID: 33391502.
      Citations: 8     Fields:    Translation:HumansCellsPHPublic Health
    2. Joshi S, Singh AR, Liu KX, Pham TV, Zulcic M, Skola D, Chun HB, Glass CK, Morales GA, Garlich JR, Durden DL. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer. Mol Cancer Ther. 2019 06; 18(6):1036-1044. PMID: 31018997.
      Citations: 15     Translation:AnimalsCells
    3. Joshi S, Durden DL. Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. J Oncol. 2019; 2019:5245034. PMID: 30853982.
      Citations: 32     
    4. Campbell GR, Bruckman RS, Herns SD, Joshi S, Durden DL, Spector SA. Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication. J Biol Chem. 2018 04 20; 293(16):5808-5820. PMID: 29475942.
      Citations: 19     Fields:    Translation:HumansCells
    5. Joshi S, Singh AR, Wong SS, Zulcic M, Jiang M, Pardo A, Selman M, Hagood JS, Durden DL. Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype. PLoS One. 2017; 12(8):e0182851. PMID: 28817691.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    6. Nguyen HA, Durden DL, Lavie A. The differential ability of asparagine and glutamine in promoting the closed/active enzyme conformation rationalizes the Wolinella succinogenes L-asparaginase substrate specificity. Sci Rep. 2017 01 31; 7:41643. PMID: 28139703.
      Citations: 3     Fields:    Translation:Cells
    7. Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR, Durden DL, Kutateladze TG. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc Natl Acad Sci U S A. 2017 02 14; 114(7):E1072-E1080. PMID: 28137841.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    8. Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, Durden DL. Association of high microvessel avß3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget. 2017 Aug 08; 8(32):52193-52210. PMID: 28881723.
      Citations: 13     Fields:    
    9. Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther. 2016 11; 15(11):2553-2562. PMID: 27496136.
      Citations: 20     Translation:HumansAnimalsCells
    10. Singh AR, Joshi S, Zulcic M, Alcaraz M, Garlich JR, Morales GA, Cho YJ, Bao L, Levy ML, Newbury R, Malicki D, Messer K, Crawford J, Durden DL. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS One. 2016; 11(3):e0150836. PMID: 26938241.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    11. Bhat V, Olmer M, Joshi S, Durden DL, Cramer TJ, Barnes RF, Ball ST, Hughes TH, Silva M, Luck JV, Moore RE, Mosnier LO, von Drygalski A. Vascular remodeling underlies rebleeding in hemophilic arthropathy. Am J Hematol. 2015 Nov; 90(11):1027-35. PMID: 26257191.
      Citations: 24     Fields:    Translation:HumansAnimals
    12. Joshi S, Singh AR, Durden DL. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. Cancer Chemother Pharmacol. 2015 Mar; 75(3):595-608. PMID: 25578041.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    13. Singh AR, Joshi S, George E, Durden DL. Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12)?V-Ha-Ras transgenic mouse glioma model. Cancer Cell Int. 2014; 14(1):105. PMID: 25425962.
      Citations: 9     
    14. Joshi S, Singh AR, Zulcic M, Durden DL. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1a and HIF2a stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res. 2014 Oct; 12(10):1520-31. PMID: 25103499.
      Citations: 48     Fields:    Translation:AnimalsCells
    15. Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, VandenBerg SR, MacDonald TJ, Durden DL. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol. 2014 Aug; 36(6):451-7. PMID: 24309609.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    16. Joshi S, Singh AR, Durden DL. MDM2 regulates hypoxic hypoxia-inducible factor 1a stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. J Biol Chem. 2014 Aug 15; 289(33):22785-22797. PMID: 24982421.
      Citations: 34     Fields:    Translation:AnimalsCells
    17. Singh AR, Peirce SK, Joshi S, Durden DL. PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment. Exp Cell Res. 2014 Sep 10; 327(1):78-90. PMID: 24881819.
      Citations: 9     Fields:    Translation:AnimalsCells
    18. Joshi S, Singh AR, Zulcic M, Durden DL. A PKC-SHP1 signaling axis desensitizes Fc? receptor signaling by reducing the tyrosine phosphorylation of CBL and regulates Fc?R mediated phagocytosis. BMC Immunol. 2014 May 07; 15:18. PMID: 24886428.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    19. Joshi S, Singh AR, Zulcic M, Bao L, Messer K, Ideker T, Dutkowski J, Durden DL. Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. PLoS One. 2014; 9(4):e95893. PMID: 24770346.
      Citations: 44     Fields:    Translation:AnimalsCells
    20. Muh CR, Joshi S, Singh AR, Kesari S, Durden DL, Makale MT. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1a suppression. J Neurooncol. 2014 Jan; 116(1):89-97. PMID: 24162827.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    21. Morales GA, Garlich JR, Su J, Peng X, Newblom J, Weber K, Durden DL. Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors. J Med Chem. 2013 Mar 14; 56(5):1922-39. PMID: 23410005.
      Citations: 12     Fields:    Translation:HumansCells
    22. De P, Dey N, Terakedis B, Bergsagel PL, Li ZH, Mahadevan D, Garlich JR, Trudel S, Makale MT, Durden DL. An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. Cancer Chemother Pharmacol. 2013 Apr; 71(4):867-81. PMID: 23355037.
      Citations: 10     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    23. Peirce SK, Findley HW, Prince C, Dasgupta A, Cooper T, Durden DL. The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother Pharmacol. 2011 Aug; 68(2):325-35. PMID: 20972874.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    24. Castellino RC, Barwick BG, Schniederjan M, Buss MC, Becher O, Hambardzumyan D, Macdonald TJ, Brat DJ, Durden DL. Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma. PLoS One. 2010 May 26; 5(5):e10849. PMID: 20520772.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    25. Crosswell HE, Dasgupta A, Alvarado CS, Watt T, Christensen JG, De P, Durden DL, Findley HW. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer. 2009 Nov 25; 9:411. PMID: 19939254.
      Citations: 23     Fields:    Translation:HumansCells
    26. Ozbay T, Durden DL, Liu T, O'Regan RM, Nahta R. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemother Pharmacol. 2010 Mar; 65(4):697-706. PMID: 19636556.
      Citations: 16     Fields:    Translation:HumansCells
    27. Gu L, Zhu N, Zhang H, Durden DL, Feng Y, Zhou M. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell. 2009 May 05; 15(5):363-75. PMID: 19411066.
      Citations: 77     Fields:    Translation:HumansCells
    28. Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009 Mar 15; 69(6):2540-9. PMID: 19276385.
      Citations: 54     Fields:    Translation:HumansCells
    29. Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, Durden DL. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 2008 Mar 15; 68(6):1862-71. PMID: 18339867.
      Citations: 83     Fields:    Translation:HumansAnimalsCells
    30. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008 Jan 01; 68(1):206-15. PMID: 18172313.
      Citations: 102     Fields:    Translation:HumansAnimalsCells
    31. Li Y, Yan J, De P, Chang HC, Yamauchi A, Christopherson KW, Paranavitana NC, Peng X, Kim C, Munugalavadla V, Munugulavadla V, Kapur R, Chen H, Shou W, Stone JC, Kaplan MH, Dinauer MC, Durden DL, Quilliam LA. Rap1a null mice have altered myeloid cell functions suggesting distinct roles for the closely related Rap1a and 1b proteins. J Immunol. 2007 Dec 15; 179(12):8322-31. PMID: 18056377.
      Citations: 71     Fields:    Translation:AnimalsCells
    32. Castellino RC, Durden DL. Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol. 2007 Dec; 3(12):682-93. PMID: 18046441.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    33. Dey N, De PK, Wang M, Zhang H, Dobrota EA, Robertson KA, Durden DL. CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation. Mol Cell Biol. 2007 Jun; 27(11):4179-97. PMID: 17325034.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    34. Reinert RB, Oberle LM, Wek SA, Bunpo P, Wang XP, Mileva I, Goodwin LO, Aldrich CJ, Durden DL, McNurlan MA, Wek RC, Anthony TG. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem. 2006 Oct 20; 281(42):31222-33. PMID: 16931516.
      Citations: 41     Fields:    Translation:AnimalsCells
    35. Rong Y, Hu F, Huang R, Mackman N, Horowitz JM, Jensen RL, Durden DL, Van Meir EG, Brat DJ. Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res. 2006 Jul 15; 66(14):7067-74. PMID: 16849552.
      Citations: 34     Fields:    Translation:HumansCells
    36. Rong Y, Durden DL, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol. 2006 Jun; 65(6):529-39. PMID: 16783163.
      Citations: 202     Fields:    Translation:HumansAnimals
    37. Dey N, Howell BW, De PK, Durden DL. CSK negatively regulates nerve growth factor induced neural differentiation and augments AKT kinase activity. Exp Cell Res. 2005 Jul 01; 307(1):1-14. PMID: 15890337.
      Citations: 12     Fields:    Translation:AnimalsCells
    38. Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 2005 Feb 15; 65(4):1406-13. PMID: 15735028.
      Citations: 64     Fields:    Translation:HumansCells
    39. Moon KD, Post CB, Durden DL, Zhou Q, De P, Harrison ML, Geahlen RL. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem. 2005 Jan 14; 280(2):1543-51. PMID: 15536084.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    40. Pradip D, Peng X, Durden DL. Rac2 specificity in macrophage integrin signaling: potential role for Syk kinase. J Biol Chem. 2003 Oct 24; 278(43):41661-9. PMID: 12917394.
      Citations: 20     Fields:    Translation:AnimalsCells
    41. Su JD, Mayo LD, Donner DB, Durden DL. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res. 2003 Jul 01; 63(13):3585-92. PMID: 12839945.
      Citations: 35     Fields:    Translation:HumansCells
    42. Erdreich-Epstein A, Tran LB, Bowman NN, Wang H, Cabot MC, Durden DL, Vlckova J, Reynolds CP, Stins MF, Groshen S, Millard M. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem. 2002 Dec 20; 277(51):49531-7. PMID: 12388538.
      Citations: 26     Fields:    Translation:HumansCells
    43. Kant AM, De P, Peng X, Yi T, Rawlings DJ, Kim JS, Durden DL. SHP-1 regulates Fcgamma receptor-mediated phagocytosis and the activation of RAC. Blood. 2002 Sep 01; 100(5):1852-9. PMID: 12176909.
      Citations: 30     Fields:    Translation:AnimalsCells
    44. Kim JS, Peng X, De PK, Geahlen RL, Durden DL. PTEN controls immunoreceptor (immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac. Blood. 2002 Jan 15; 99(2):694-7. PMID: 11781256.
      Citations: 12     Fields:    Translation:AnimalsCells
    45. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2002 Feb 15; 277(7):5484-9. PMID: 11729185.
      Citations: 97     Fields:    Translation:HumansCells